Lantheus Holdings is a biotechnology company that specializes in developing and commercializing innovative diagnostic imaging agents and therapeutics primarily for oncology and other conditions
Their products include advanced molecular imaging agents that enhance the visualization of diseases in patients, enabling healthcare providers to make more informed decisions about diagnosis and treatment. The company is committed to advancing patient care through its focus on precision medicine, utilizing cutting-edge technologies to improve the detection and management of various diseases, particularly cancers, thus helping clinicians optimize patient outcomes.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQLNTH)
jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings topping analysts' expectations. Sales rose 10.5% year-on-year, fueled by high demand for its radiopharmaceutical products, including PYLARIFY, which crossed $1 billion in annual sales.
For 2025, the company set a bullish earnings forecast, well above consensus estimates. However, its full-year revenue outlook came in slightly below expectations, pointing to a more cautious growth path.
Overall, the quarter was decent, showcasing areas of strength in key product lines while highlighting some challenges, particularly in balancing revenue growth with increased spending on future initiatives.
Radiopharmaceutical company Lantheus Holdings (NASDAQLNTH) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.5% year on year to $391.1 million. On the other hand, the company’s full-year revenue guidance of $1.58 billion at the midpoint came in 2.3% below analysts’ estimates. Its non-GAAP profit of $1.59 per share was 3% above analysts’ consensus estimates.
LANTHEUS HOLDINGS INC was identified as a growth stock that isn't overvalued. NASDAQ:LNTH is excelling in various growth indicators while maintaining a solid financial footing.
Uncover the potential of LANTHEUS HOLDINGS INC, an undervalued stock. NASDAQ:LNTH maintains a strong financial position and offers an appealing valuation.
LANTHEUS HOLDINGS INC was identified as an affordable growth stock. NASDAQ:LNTH is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
LANTHEUS HOLDINGS INC has a stellar value proposition. NASDAQ:LNTH not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
Based on a technical and fundamental analysis of NASDAQ:LNTH we ask: Is LANTHEUS HOLDINGS INC (NASDAQLNTH) on the Verge of a Major Breakout as a Strong Growth Stock?
Short-term market predictions are fun, but rarely worth investing in. Here are two stocks we think will be winners no matter what happens with the market in 2025.
